BeiGene of Beijing has been granted priority review by the NMPA for tislelizumab, the company's PD-1 immunotherapy, as a treatment for urothelial carcinoma (UC), the most common form of bladder cancer. It is the second indication to receive priority review. In November 2018, the NMPA agreed to review the candidate under priority rules for relapsed/refractory (R/R) classic Hodgkin’s lymphoma (cHL). BeiGene said it is testing tislelizumab in 13 pivotal or potentially registration-enabling trials. More details....
Stock Symbols: (NSDQ: BGNE; HKEX: 06160)
Share this with colleagues:
Original Article: BeiGene Granted Second China Priority Review for PD-1 Candidate